𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Thymosin α1 treatment of chronic hepatitis B: A multicenter, randomized, placebo-controlled double blind study

Book ID
122937913
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
174 KB
Volume
108
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy with thymosin α1 and
Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

Sulfasalazine in the treatment of juveni
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
✍ Marion A. J. van Rossum; Theo J. W. Fiselier; Marcel J. A. M. Franssen; Aeilko H 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 987 KB

Objective. To assess the efficacy, tolerability, and safety of sulfasalazine (SSZ) in the treatment ofjuvenile chronic arthritis (JCA). Methods. We conducted a 24-week randomized, placebo-controlled, double-blind, multicenter study of patients with active JCA of both oligoarticular and polyarticula

Thymosin treatment of chronic hepatitis
Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial
✍ Milton G. Mutchnick; Henry D. Appelman; H. T. Chung; Emma Aragona; Tej P. Gupta; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 828 KB

Chronic hepatitis B is a severe and frequently progressive disease. We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liv